Arkolith/Insider Trading/AVTX/Form 4

Sullivan Christopher Ryan

Chief Financial OfficerAvalo Therapeutics, Inc. (AVTX) · full profile →Form 4 · filed Mar 31, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 28, 2026Tax withholding(F)8K$13.89$114K33K
Mar 28, 2026Option exercise(M)24K——42K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 28, 2026Option exercise(M)24K—$024K

Transaction Codes

F
Shares withheld for taxes
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001810417-26-000004) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML